The Multinational Association for Supportive Care in Cancer (MASCC) risk index can be used to identify low-risk patients (score cut off at 21 points) for serious complications of febrile neutropenia. Per 2010 guidelines from Infectious Diseases Society of America
- Cefepime, carbapenems or piperacillin/tazobactam are recommended for high-risk patients and
- Co-amoxiclav and ciprofloxacin are recommended for low-risk patients.
Patients who do not strictly fulfill the criteria of low-risk patients should be admitted to the hospital and treated as high-risk patients.